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boOBJECTIVES This study compared the timing of onset of antiplatelet action after treatment with clopidogrel and
prasugrel at ﬁrst medical contact in patients with ST-segment elevation myocardial infarction (STEMI) scheduled for
primary percutaneous coronary intervention (PPCI).
BACKGROUND Little is known about the timing of onset of antiplatelet action after a pre-percutaneous coronary
intervention (PCI) loading dose of clopidogrel or prasugrel in patients with STEMI.
METHODS This double-blind, prospective study randomized 62 patients with STEMI scheduled for PPCI in the ambu-
lance or the emergency department to 60 mg prasugrel (n ¼ 31) or 600 mg clopidogrel (n ¼ 31). The primary endpoint
was the platelet reactivity index (PRI) measured with the vasodilator-stimulated phosphoprotein assay 2 h after intake of
the study medication. Secondary endpoints were PRI after 4 h, TIMI (Thrombolysis In Myocardial Infarction) patency of
the infarct-related artery before and after PCI, and clinical events until day 30.
RESULTS The PRI after 2 h (50.4  32.7% vs. 66.3  22.2%; p ¼ 0.035) and after 4 h (39.1  27.5% vs. 54.5  49.3%;
p ¼ 0.038) were signiﬁcantly lower with prasugrel compared with clopidogrel. In addition, the rate of patients with a
PRI <50% tended to be higher with prasugrel compared with clopidogrel after 2 h (46.7% vs. 28.6%; p ¼ 0.15) and after
4 h (63.0% vs. 38.9%; p ¼ 0.06). There were no signiﬁcant differences in TIMI 2/3 patency before PCI (39.2% vs. 31.0%;
p ¼ 0.43) and TIMI 3 patency after PCI (88.5% vs. 89.3%; p ¼ 0.92).
CONCLUSIONS The pre-PCI administration of prasugrel in patients with STEMI undergoing PPCI was associated with a
signiﬁcant faster platelet inhibition compared with clopidogrel. Therefore, prasugrel should be preferred to clopidogrel in
this setting. (ETAMI-Study: Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute Myocardial
Infarction; NCT01327534) (J Am Coll Cardiol Intv 2015;8:147–54) © 2015 by the American College of Cardiology
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148E ffective platelet inhibition is acornerstone of therapy in patientswith ST-segment elevation myocar-
dial infarction (STEMI) (1,2). In several ran-
domized trials, acetylsalicylic acid has been
shown to improve short- and long-term clin-
ical outcome after STEMI; therefore, it is rec-
ommended as standard therapy in recent
guidelines (1,2). The thienopyridine clopi-
dogrel acts synergistically with acetylsali-
cylic acid and improved outcome in
patients with STEMI without primary percu-
taneous coronary intervention (PPCI) in the
COMMIT (Clopidogrel and Metoprolol inMyocardial Infarction Trial) (3). However, in pa-
tients with STEMI scheduled for PPCI, a fast, effective
inhibition of adenosine diphosphate (ADP)-induced
platelet aggregation, preferably within 60 to 90 min
after administration of the drug, is desirable, which
in most cases cannot be achieved with clopidogrel
(4). The new thienopyridine prasugrel has been
shown to achieve a more complete and even more
rapid platelet inhibition compared with clopidogrel
in healthy volunteers (5). This has been shown to
be especially beneﬁcial in patients with STEMI
scheduled for PPCI (6). In these patients, activation
of platelets is more pronounced compared with
healthy volunteers or with patients undergoing per-
cutaneous coronary intervention (PCI) for stable cor-
onary artery disease (7). In a small substudy of the
TRITON-TIMI 38 (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet In-
hibition with Prasugrel—Thrombolysis In Myocardial
Infarction-38), inhibition of platelet aggregation
measured with the vasodilator-stimulated phospho-
protein (VASP) assay was more effective with pra-
sugrel than with clopidogrel (8). However, this
substudy was done predominantly in patients with
non–ST-segment elevation ACS. In addition, none of
these patients were treated in the pre-hospital phase.
Nowadays, antithrombotic therapies in patients with
STEMI are often given in the ambulance or at ﬁrst
medical contact. Therefore, it is necessary to deter-
mine if, in patients with acute STEMI, an early admin-
istration of a high loading dose of prasugrel inEli Lilly. Dr. Thiele has received research funding from Eli Lilly
kyo, AstraZeneca, and Boehringer Ingelheim. Dr. Montalescot h
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received June 20, 2014; revised manuscript received August 15,comparison with clopidogrel before planned PPCI im-
proves the speed and intensity of inhibition of
platelet aggregation, which might have contributed
to the improvement in clinical outcome observed in
the TRITON-TIMI 38 trial (9). However, recent studies
suggest that platelet inhibition in patients with
STEMI, even with prasugrel, is deferred compared
with healthy volunteers and is not optimal about 2 h
after intake of the loading dose (10–12).
METHODS
STUDY DESIGN. ETAMI (Early Thienopyridine Treat-
ment to Improve Primary PCI in Patients With Acute
Myocardial Infarction) was an international, double-
blind, randomized, prospective, 2-arm study. The
study was approved by the local ethics committees of
the participating centers. All patients gave written
informed consent. The study has been registered at
ClinicalTrials.gov as NCT01327534.
OBJECTIVES AND PATIENT POPULATION. The objec-
tive of the ETAMI trial was to compare the efﬁcacy of
a 60 mg loading dose of prasugrel followed by a 10 mg
maintenance dose with a 600 mg loading dose of
clopidogrel followed by a 75 mg maintenance dose in
patients with acute STEMI scheduled for PPCI with
respect to inhibition of platelet aggregation. The
loading dose was given at ﬁrst medical contact either
in the pre-hospital setting or in a PCI hospital if the
expected time until the start of the scheduled PPCI
was at least 20 min. The inclusion criteria were:
age $18 years and <75 years; acute STEMI #12 h
deﬁned as: 1) angina or equivalent symptoms >30
min; or 2) ST-segment elevation $2 electrocardiogram
leads ($2 mm precordial leads, $1 mm limb leads, or
ST depression $1 mm pre-cordial leads in posterior
myocardial infarction); planned PPCI; legal capacity
(including ability to understand the nature, scope,
and possible consequences of the study participa-
tion); and informed consent. Exclusion criteria
included: age $75 years; body weight <60 kg;
thrombolytic therapy within 24 h before randomiza-
tion; oral anticoagulation; known hemorrhagic
diathesis; history of stroke or transient ischemic
attack; cardiogenic shock; evidence of an active; and has received speakers honoraria from Eli Lilly,
as received consulting fees from Bayer, Boehringer
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149gastrointestinal or urogenital bleeding; major surgery
within 6 weeks; contraindication to prasugrel or clo-
pidogrel; severe renal or hepatic insufﬁciency;
contraindication to coronary angiography; planned
administration of a glycoprotein (GP) IIb/IIIa inhibitor
before angiography; pregnant or nursing (lactating)
women; treatment within the last 10 days with clo-
pidogrel, prasugrel, ticlopidine, or ticagrelor; uncon-
trollable hypertension (blood pressure $200/110
mm Hg in repeated measurements); treatment with
NSAIDs; and participation in another clinical or de-
vice trial within the previous 30 days.
STUDY PROCEDURES. In the ambulance or in the
emergency department of a PCI hospital after diag-
nostic conﬁrmation of STEMI, all patients received a
baseline treatment of aspirin (500 mg intravenously
or 300 mg orally). Patients in the prasugrel group
received a loading dose of 60 mg prasugrel and 8
tablets of clopidogrel placebo, and patients in the
clopidogrel group received a loading dose of 600 mg
clopidogrel and 6 tablets of prasugrel placebo as early
as possible. Randomized patients were transferred to
the catheterization laboratory, where diagnostic cor-
onary angiography and PPCI with stent implantation
was done according to the local guidelines but within
3 h after randomization. The administration of GP IIb/
IIIa inhibitors after the diagnostic angiography and
prior to or during PPCI was left to the discretion of the
treating physician. Blood for the determination of the
platelet reactivity index (PRI) was drawn 120 and 240
min after administration of the double-blind study
medication, and all samples were processed within 24
h after collection. PRI was measured with CY-QUANT
VASP/P2Y12 assay (Stago, Parsippany-Troy Hills, New
Jersey).
DEFINTION OF ENDPOINTS. Plate let react iv i ty
index . VASP phosphorylation data were expressed as
PRI in percent, deﬁned as:
ðMFI ½PGE1 MFI ½PGE1þ ADPÞ=MFI ½PGE1  100
where MFI indicates mean ﬂuoroscopy intensity, and
PGE1 indicates prostaglandin E1. A lower PRI in-
dicates a greater antiplatelet effect. Sufﬁcient PRI
was deﬁned as <50% (13).
Patency of the infarcted vessel before and after
PCI . Based on the TIMI (Thrombolysis In Myocardial
Infarction) classiﬁcation, patency of infarct-related
coronary arteries was evaluated, centralized, and
blinded in a core laboratory (14).
Reinfarct ion . Within the ﬁrst 48 h after primary
event: recurrent angina and recurrent increase
of creatine kinase-MB over 50% of the last level
or over the norm (if creatine kinase-MB hasalready normalized) or angiographic documentation
of reocclusion.
Bleed ing compl i cat ions . Safety endpoints were
bleeding complications according to the GUSTO
(Global Utilization of Streptokinase and TPA for Oc-
cluded Coronary Arteries) (15) and TIMI (14) criteria.
STATISTICS. The primary aim of the study was a
statistical comparison of the PRI measured by VASP
phosphorylation 2 h after the initiation of the therapy
in the study groups A and B. So, the statistical
approach was formulated as follows:
Hypothesis: the expected mean PRI in both groups
is the same.
Alternative: the expected mean PRI in both groups
is different.
In a homogeneous target population, we assumed
that PRI could be modeled as a continuous random
variable whose distribution was characterized by the
expected value m. With the indexes A and B we signed
the deﬁned groups.
Hypothesis : mA ¼ mB
Alternative : mAsmB
The test level alpha was 5%. The statistical test for
the primary target parameter was the Satterthwaite’s
t-test for comparing means with unequal SDs. The
mean difference was estimated, and a corresponding
conﬁdence interval was calculated.
The secondary target parameters underwent
descriptive analyses, and explorative statistical eval-
uation was performed for comparing the 2 groups.
All statistical analyses were performed with the
“intention-to-treat” dataset.
Assuming a PRI of 75  15% in the clopidogrel
group (group B), a PRI of 60  25% in the prasugrel
group (group A), a power of 80%, and an alpha error
of 5%, 31 patients per group were needed.
RESULTS
Between December 2011 and March 2013, a total of 63
patients were enrolled in 4 centers: 31 were ran-
domized to clopidogrel and 32 to prasugrel. One pa-
tient in the prasugrel group withdrew informed
consent and was excluded from the analysis. The
patient ﬂow chart is given in Figure 1. The baseline
characteristics of the 2 groups are given in Table 1
and did not show any signiﬁcant differences
between the 2 groups. All patients received the
double-blind study medication. In these 62 patients
fulﬁlling the inclusion criteria, STEMI was conﬁrmed
in 57 cases (28 prasugrel, 29 clopidogrel), whereas in
5 cases, the initial diagnosis was not conﬁrmed
FIGURE 1 Study Flow Chart of the Design and Patients of the Study
Depicted are the patients randomized, the intention-to-treat (ITT) population, and patients with the ﬁnal diagnosis of ST-segment elevation
myocardial infarction (STEMI). FU ¼ follow-up; Pat ¼ patients; PRI ¼ platelet reactivity index.
TABLE 1 Baseline Characteristics of Patients Randomized to
Prasugrel or Clopidogrel
Prasugrel
(n ¼ 31)
Clopidogrel
(n ¼ 31) p Value
Mean age, yrs 59.0 (55–70) 64.0 (49–70) 0.45
Women 10 (32.3) 7 (22.6) 0.39
Medical history
Prior myocardial infarction 2 (6.5) 3 (9.7) 0.64
Prior PCI 3 (9.7) 4 (12.9) 0.68
Prior coronary artery
bypass grafting
0 0
Coronary risk factors
Hypertension 17 (54.8) 17 (54.8) 1.0
Hyperlipidemia 15 (48.4) 12 (38.7) 0.44
Diabetes mellitus 6 (19.4) 6 (19.4) 1.0
Smoker within last
12 months
24 (78.4) 22 (71) 0.56
Values are median (interquartile range) or n (%).
PCI ¼ percutaneous coronary intervention.
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150(3 and 2 patients, respectively). A PRI value 2 h after
the loading dose was not available in 3 patients; in
addition, for 1 patient, the actual diagnosis turned
out to be pulmonary embolism, and for this patient,
study guidance decided that his data should not be
included in the intention-to-treat analysis of PRI
values. The time intervals between symptom onset
and ﬁrst medical contact (median 60 min, 35 to
128 min vs. median 85 min, 44 to 194 min; p ¼ 0.08),
ﬁrst medical contact to study drug (40 min, 9 to
56 min vs. 52 min, 10 to 64 min; p ¼ 0.55), study drug
to coronary angiography (15 min, 7 to 42 min vs.
23 min, 5 to 43 min; p ¼ 0.87) and study drug to
blood sampling for PRI (120 min, 110 to 130 min vs.
120 min, 109 to 131 min) did not signiﬁcantly differ
between the 2 groups.
The TIMI patency rates of the infarct-related artery
as evaluated in a central core laboratory are shown in
Table 2. PPCI was performed in 26 and 28 patients,
TABLE 2 Angiographic Findings and Interventional Features
Prasugrel
(n ¼ 31)
Clopidogrel
(n ¼ 31) p Value
Angiography performed 31 (100) 31 (100) 0.99
No STEMI 3 2
STEMI 28 29
Patency of the infarct-related
artery before PPCI
TIMI ﬂow grade 0/1 17 (60.7) 20 (69.0) 0.76
TIMI ﬂow grade 2 4 (14.2) 2 (6.9)
TIMI ﬂow grade 3 7 (25.0) 7 (24.1)
TIMI ﬂow grade 2/3 11 (39.2) 9 (31.0) 0.43
PPCI performed 26 28
Stent 25 (96.2) 25 (89.3)
Patency of the infarct related
artery after PPCI
TIMI ﬂow grade 0/1 0 0 0.92
TIMI ﬂow grade 2 3 (11.5) 3 (10.7)
TIMI ﬂow grade 3 23 (88.5) 25 (89.3)
Values are n (%) or n.
PPCI ¼ primary percutaneous coronary intervention; STEMI ¼ ST-segment
elevation myocardial infarction; TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 4 Results of the PRI Measurements in the 2 Groups
Prasugrel
(n ¼ 31)
Clopidogrel
(n ¼ 31) p Value
PRI
Baseline 76.2  16.0 76.7  22.3 0.94
2 h 50.4  32.7 66.3  22.2 0.035
4 h 39.2  29.3 54.5  24.1 0.038
Rate of patients with PRI <50%
2 h 14/30 (46.7) 8/28 (28.6) 0.15
4 h 17/27 (63.0) 11/29 (37.9) 0.06
Values are mean  SD or n/N (%).
PRI ¼ platelet reactivity index.
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151respectively, and TIMI ﬂow grade 3 patency after PCI
was not different between the 2 groups. The
concomitant medication administered in the acute
phase is given in Table 3 and did not show any sig-
niﬁcant differences between the 2 groups.
The PRI at baseline was 76% in the 2 groups
(Table 4). The primary endpoint PRI after 2 h as well
as the secondary endpoint PRI after 4 h were signiﬁ-
cantly lower with prasugrel compared with clopi-
dogrel in the intention-to-treat analysis (Table 4). The
time-course of PRI is given in Figure 2. The distribu-
tion of PRI is given in Figure 3 and showed a wide
variability both with clopidogrel and prasugrel. In the
patients with conﬁrmed STEMI, PRI was lower in
the prasugrel-treated compared with the clopidogrel-TABLE 3 Periprocedural Antithrombotic and Adjunctive
Therapy During the First 48 h
Prasugrel
(n ¼ 31)
Clopidogrel
(n ¼ 31) p Value
ASA 31 (100) 31 (100) 0.9
GP IIb/IIIa inhibitors 4 (12.9) 2 (6.4) 0.31
Unfractionated heparin 28 (90.3) 30 (96.8) 0.3
Enoxaparin 2 (6.5) 0 0.15
Bivalirudin 17 (54.8) 15 (48.4) 0.6
Beta-blockers 24 (77.4) 28 (90.3) 0.16
ACE inhibitors/ARBs 28 (90.3) 29 (93.5) 0.64
Statins 27 (87.1) 28 (90.3) 0.68
Morphine 19 (61.3) 13 (41.9) 0.12
Values are n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blockers;
ASA ¼ acetylsalicylic acid; GP ¼ glycoprotein.treated patients both after 2 h (48.7  31.6% vs. 65.3 
22.1%; p ¼ 0.04) and 4 h (38.9  28.1% vs. 54.7 
24.5%; p ¼ 0.03). The rate of patients with a sufﬁcient
PRI of <50% tended to be higher with prasugrel
compared with clopidogrel after 2 and 4 h (Table 4).
Clinical events until day 30 were rare and are listed
in Table 5. Bleeding complications were observed
only in 1 and 0 patients, respectively.
DISCUSSION
ETAMI is the ﬁrst randomized, double-blind study to
compare the pre-PCI administration of loading doses
of 600 mg clopidogrel and 60 mg prasugrel in patients
with STEMI scheduled for PPCI. The principal resultFIGURE 2 Time Course of the PRI Measured With the VASP Assay
Time course of the median values of the platelet reactivity index (PRI) measured with
the vasodilator-stimulated phosphoprotein (VASP) assay in the 2 groups randomized to
prasugrel or clopidogrel at baseline and 2 and 4 h after intake of the study medication.
FIGURE 3 Distribution of Individual PRIs After 2 and 4 Hours
Distribution of individual platelet reactivity indexes (PRI) after (A) 2 h and (B) 4 h in the
2 patient groups randomized to prasugrel or clopidogrel.
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152of the study is that prasugrel achieves a faster and
more intense inhibition of platelet inhibition than
clopidogrel. After prasugrel, about 50% and 65% of
the patients will have a VASP index of <50% within
2 and 4 h, respectively, whereas with clopidogrel,
these rates are around 30% and 40%, respectively.
That means that 60% of patients with STEMI will
have insufﬁcient inhibition of platelet aggregation
within 4 h after intake of clopidogrel compared with
only one-third after prasugrel.
The strength of our study was the randomized,
double-blind design, which excludes any bias asso-
ciated with nonrandomized comparisons or open
randomized trials. The 600-mg loading dose of clo-
pidogrel was selected because it has been shown thatit achieves a faster and more effective platelet inhi-
bition than the approved 300-mg loading dose in
randomized trials (4,16). This effect was associated
with an improved clinical outcome of 600 to 300 mg
clopidogrel in patients with primary PCI (16,17) and
in PCI, in patients with ACS with and without
ST-segment elevation (18). However, in a randomized
trial, the pre-hospital administration of 600 mg clo-
pidogrel did not signiﬁcantly improve patency of the
infarct-related artery before PCI compared with the
control group (19). Because in this trial the clopidog-
rel was given at a mean of 47 min before angiography,
only a few patients have had a sufﬁcient level of in-
hibition of platelet aggregation according to the re-
sults of the present study.
Randomized data on the results of platelet func-
tion tests in patients undergoing primary PCI for
STEMI treated by clopidogrel or prasugrel are scarce.
We have chosen the VASP-PRI as primary outcome
because the result is not affected by the concomitant
use of GP IIb/IIIa inhibitors and the results correlate
well with those of platelet aggregometry and tests of
activation by ﬂow cytometry (20). In addition, it can
be stored for up to 48 h without affecting the results,
which makes the tests highly suitable for an acute
study with STEMI patients. However, faster process-
ing of blood samples might be associated with more
reliable and reproducible results (21); therefore, all
samples in our study were handled within 24 h after
collection.
The pharmacodynamic substudy of the TRITON–
TIMI 38 trial (8) included only 4 patients with STEMI.
In the overall population, in 99 evaluable patients
60 mg prasugrel compared with 300 mg clopidogrel
showed a more potent platelet inhibition assessed
with the VASP-PRI 1 to 2 h after loading dose and PCI
(51.8% vs. 78.8%, p ¼ 0.001). In healthy volunteers,
prasugrel was associated with an even faster onset
of action. Effective ADP receptor inhibition was
observed within 30 min in most volunteers, whereas
300 mg clopidogrel needed several hours to become
effective (22). In a nonrandomized comparison, a
60mg prasugrel loading dose about 50min before PPCI
was associatedwith a better inhibition of ADP-induced
platelet aggregation compared with a 600 mg loading
dose of clopidogrel (23). However, only 47% of patients
after prasugrel and 29% after clopidogrel achieved
an adequate platelet inhibition, deﬁned as ADP-
induced platelet aggregation of <70%, during a
clinically-relevant door-to-balloon time of about 50
min. Another observational study observed again
more effective platelet inhibition and a trend toward a
better angiographic outcome before and after PPCI
with prasugrel compared with clopidogrel (24). These
TABLE 5 Clinical Events Until Day 30 or Hospital Discharge
Prasugrel
(n ¼ 31)
Clopidogrel
(n ¼ 31) p Value
Death 1 1 1.00
Cardiogenic shock 1 2 0.27
Reinfarction 0 0 1.0
Stent thrombosis 0 0 1.0
Stroke 0 0 1.0
TIMI major or minor bleeding 1 0 0.31
GUSTO major or moderate bleeding 1 0 0.31
TIMI ¼ Thrombolysis In Myocardial Infarction.
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153results support our ﬁndings of a signiﬁcantly faster
onset of platelet inhibition with prasugrel compared
with clopidogrel in patients with primary PCI.
In the randomized TRITON-TIMI 38 trial and in
observational nonrandomized studies, prasugrel was
associated with an improved clinical outcome in
patients with PPCI for STEMI (8,25,26). These ﬁnd-
ings might be explained at least in part by the faster
and more potent platelet inhibition, as shown in our
trial.
In 2 studies comparing the antiplatelet effects of
prasugrel and ticagrelor in patients with PPCI, no
signiﬁcant differences were reported between these
drugs (10,11). However, in both trials, around 50% of
patients did not achieve adequate platelet inhibition
as assessed by different methods 2 h after the loading
dose.
We observed a wide patient variability of the
response to the 2 drugs, which was more pronounced
with clopidogrel, suggesting that the gastrointes-
tinal absorption of orally-administered drugs may be
limited or delayed in STEMI patients for multiplereasons, including reduced or delayed drug adsorp-
tion in patients with hemodynamic disarrangement,
systemic vasoconstriction, adrenergic activation, and
a high risk of vomit (27).
Therefore, it might be necessary to use faster-
acting antiplatelet drugs to achieve an adequate
level of platelet inhibition at the time of PPCI. One
option is GP IIb/IIIa inhibitors, such as tiroﬁban,
which was associated with a more potent platelet in-
hibition than prasugrel in the randomized FABOLUS-
PRO (Facilitation through Aggrastat By drOpping or
shortening Infusion Line in patients with ST-segment
elevation myocardial infarction compared to on top of
PRasugrel given at loading dOse) trial (12). Another
candidate is cangrelor, an intravenous ADP-receptor
inhibitor with a rapid onset of action and a short
half-life (28).
CONCLUSIONS
The pre-PCI administration of prasugrel in patients
with STEMI undergoing primary PCI was associated
with signiﬁcantly faster ADP receptor inhibition
compared with clopidogrel. Therefore, prasugrel
should be preferred to clopidogrel in this patient
population. However, even with prasugrel, inhibition
of ADP-induced platelet aggregation is not as fast
as in healthy volunteers and is still not optimal within
2 h after a loading dose of 60 mg.
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